News from the BioRegion STERN

Round led by existing investors Meneldor and High-Tech Gründerfonds Proceeds to be used to start Phase II study with ATR-002 in moderate to severe COVID-19 and clinical development in influenza and other respiratory viral infections ATR-002 mode of action inhibits viral propagation of respiratory RNA viruses and prevents the cytokine storm, ...

TÜBINGEN, Germany/ BOSTON, USA – August 10, 2020 – CureVac B.V. (“CureVac” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer and sell in an underwritten public offering of 13,333,333 common share...

Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP manufacturing infrastructure at The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory Collaboration ensures continued clinical batch supply for all of Immatics’ ongoing and next Adoptive Cell Therap...

TÜBINGEN, Germany/ BOSTON, USA – August 4, 2020 – CureVac today announced that Dr. Franz-Werner Haas, previously acting Chief Executive Officer and Chief Operating Officer (COO), has been appointed Chief Executive Officer (CEO).

As a partner in the Chiramet research consortium Insilico Biotechnology has identified methods to increase the productivity of biological cells to manufacture chiral building blocks from methanol.

Expand your horizon on resection techniques in endoluminal surgery.

stentfix OTSC was used in five complex cases who already had experienced stent migration and were considered unfit for surgery. Placement of stentfix OTSC resulted in immediate technical success in all patients. Stent migration or fixation-related adverse events did not occur in any patient.

Financing Round includes previously announced investments from German Federal Government and GSK for an amount of USD 514 Million   Additional USD 126 million raised, including participation of Qatar Investment Authority (QIA)    

Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases   GSK to make equity investment of £130m (€150m) in CureVac, and an upfront payment of £104m (€120m)    

Houston, Texas and Tuebingen, Germany, July 9, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced changes to its Board of Directors in conjunction with its recent listing on NASDAQ. Michael Atieh, Paul ...

92 patients with 117 non-acute full-thickness gastrointestinal defects (65 fistulas, 52 leaks) underwent OTSC therapy. With a median follow-up time of 5.5 months, overall defect closure success rate was 66.1 %. Only 14.9 % of patients underwent opera...

European Investment Bank and CureVac sign €75 million loan agreement for the development and large-scale production of vaccines, including CureVac’s vaccine candidate against SARS-CoV-2 The EIB loan will support CureVac’s activities to complete its new messenger ribonucleic acid (mRNA) production facility in Tübingen, Germany The transaction...

The business combination transaction with Arya Sciences Acquisition Corporation, a special purpose acquisition company sponsored by Perceptive Advisors, was completed on July 1, 2020 The combined company was renamed Immatics N.V. Immatics common stock and warrants will commence trading today on the Nasdaq Capital Markets under the ticker sym...

(Stuttgart) Insilico Biotechnology AG launches new data connectivity solution for coping with increased demand for predictive solutions in biologics manufacturing and process development.

For the first time, research explains the cascade of events linking influenza virus-induced activation of the Raf/MEK/ERK pathway to the nuclear export of viral ribonucleoprotein (vRNP) via the host protein RSK   Raf/MEK/ERK/RSK pathway represents an Achilles heel of virus replication and is a target of the ongoing antiviral development by...

New York, NY, Houston, TX and Tuebingen, Germany, June 29, 2020 – Arya Sciences Acquisition Corp. (NASDAQ: ARYA or “Arya”), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting c...